Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 12/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.35 |
| ▸ | GGT1 | P19440 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24678191 | 0.84 | KDM4E (0.34) | FOLH1NOD1ALDH1A1KDM4E | |
| SCHEMBL24703969 | 0.84 | KDM4E (0.34) | FOLH1NOD1ALDH1A1KDM4E | |
| SCHEMBL18377220 | 0.84 | FOLH1 (0.40) | FOLH1NOD1ALDH1A1KDM4EMEN1 | |
| SCHEMBL13262513 | 0.84 | FOLH1 (0.40) | FOLH1NOD1ALDH1A1KDM4EMEN1 | |
| SCHEMBL26743889 | 0.84 | FOLH1 (0.43) | FOLH1NOD1GGT1 | |
| SCHEMBL22309224 | 0.82 | FOLH1 (0.39) | FOLH1NOD1ALDH1A1KDM4EMEN1 | |
| SCHEMBL19700526 | 0.81 | MMP3 (0.38) | FOLH1NOD1 | |
| SCHEMBL21689984 | 0.81 | GPR84 (0.50) | FOLH1NOD1 | |
| SCHEMBL13167819 | 0.81 | FOLH1 (0.63) | FOLH1KDM4ESMN1; SMN2 | |
| SCHEMBL24004559 | 0.81 | SMN1; SMN2 (0.52) | FOLH1NOD1ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220025071-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220025071-A1 | TETRAHEDRAL ANTIBODIES | FCGR3B, FCGR2A, FCGR1A | FOLH1 212/4885NOD1 839/4885ALDH1A1 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.